New CRISPR Tool Targets Cancer Cells by Reading DNA Methylation
Updated
Updated · Nature.com · Apr 15
New CRISPR Tool Targets Cancer Cells by Reading DNA Methylation
6 articles · Updated · Nature.com · Apr 15
Scientists have developed ThermoCas9, a CRISPR variant that can selectively target and cut tumor DNA by recognizing disease-specific methylation patterns.
This methylation-sensitive gene editing enables ThermoCas9 to distinguish cancer cells from healthy cells, demonstrating selective activity in breast and colorectal cancer models.
The approach could lead to more precise cancer therapies and may be adaptable for other diseases marked by abnormal DNA methylation, pending further research.
Discovered in compost, a new enzyme targets cancer. How does this code-reader promise a revolution in precision medicine?
A new CRISPR selectively destroys tumor DNA. What are the risks of editing the epigenome, our cells' instruction manual?
This cancer-killing CRISPR works at 60°C. How will scientists adapt this heat-loving enzyme for the human body?
Beyond cancer, could this gene editor one day reverse diseases like autoimmune disorders by targeting their epigenetic roots?
If cancer cells can be targeted by their unique epigenetic code, could they also change that code to hide?
Harnessing ThermoCas9’s Methylation-Sensitive CRISPR Mechanism for Next-Generation Cancer Treatments
Overview
On April 15, 2026, researchers from Wageningen University & Research and the Van Andel Institute published a breakthrough study unveiling ThermoCas9, a CRISPR tool that selectively cuts cancer DNA by recognizing unique methylation patterns. This ability stems from ThermoCas9's sensitivity to methylated DNA sequences, allowing it to target tumor cells while sparing healthy tissue. Supported by major funding, ThermoCas9 has been experimentally validated in breast cancer cells and shows promise for cancer therapy, especially when combined with immunotherapy. However, challenges like delivery, immune reactions, and tumor methylation variability mean clinical trials are still 5 to 8 years away.